The global Biologics Contract Manufacturing Market was valued at USD 17.45 billion in 2021 and it is expected to reach USD 30.9 billion by 2030 with a CAGR of 8.4% during the prediction period 2022 to 2030.
The global Biologics Contract Manufacturing Market was valued at USD 17.45 billion in 2021 and it is expected to reach USD 30.9 billion by 2030 with a CAGR of 8.4% during the prediction period 2022 to 2030.
The success of the biopharmaceutical market can be majorly attributed to the contract manufacturers. Reduction in the overall investment required to bring a new drug product to market, providing access to expensive technologies, quick entry of products in the markets, and greater flexibility are some advantages offered by Contract Manufacturing Organizations (CMOs), which have prompted the companies to outsource their biopharmaceutical manufacturing. Furthermore, with a perpetual expansion of the biopharmaceutical industry, companies are facing production issues, such as lack of expertise and sophisticated equipment, while practicing in-house manufacturing.
Get the sample copy of report@ https://www.novaoneadvisor.com/report/sample/6297
The maturity of biotechnology and the availability of external funding has resulted in the growth in the number of early-stage bio/pharma companies. These companies are recognized as core customers of CMOs as these organizations lack the capabilities for the development of robust manufacturing operations. Key players are going for capacity expansion to fulfill the growing demand. For instance, in 2020, Thermo Fisher Scientific announced an investment of USD 180.0 million for the construction of a new commercial manufacturing site in Plainville, Mass for viral vector development and manufacturing services. In 2019, Boehringer Ingelheim invested USD 84 million for the expansion in Mexico to increase production.
| Report Scope | Details |
| Market Size By 2030 | USD 30.9 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 8.4% |
| Largest Market | North America |
| Fastest Growing Region | Asia Pacific |
| Companies Covered | Boehringer Ingelheim GmbH; Lonza; Inno Biologics Sdn Bhd; Rentschler Biotechnologie GmbH; JRS Pharma; AGC Biologics; ProBioGen; Fujifilm Diosynth Biotechnologies U.S.A., Inc.; Toyobo Co., Ltd.; Samsung BioLogics |
Service Insights
Process development services led the global market in 2021 and accounted for a share of over 34.1%. This is due to high capital expenditure in downstream processing. Moreover, downstream operations demand vigorous attention for final product recovery and purification steps to maintain product quality and prevent wastage.
With the growing quality concerns and regulatory changes for biopharmaceutical development, the analytical & QC studies segment is expected to record the fastest CAGR during the forecast period. New regulations are being introduced for the production of biologics by CMOs in compliance with regulatory standards to maintain product purity and safety.
Ask here for customization@ https://www.novaoneadvisor.com/report/customization/6297
Product Insights
Although, contract manufacturers have played a vital role in the success of both biologics and biosimilars; the biologics product segment led the market in 2020 with a share of over 80%. The segment will maintain the dominant position throughout the forecast period due to the huge commercial success of biologics, which is depicted through the presence of a large number of FDA-approved biologics in the market.
Among all the biologics, Monoclonal Antibodies (MAb) have captured the largest share in 2020. A high capital requirement for the construction of a MAb plant has accelerated the uptake of contract services for Mab production, thereby contributing to the segment’s growth.
However, the biosimilars segment is estimated to register the fastest CAGR over the forecast period. This is because biosimilars production is one of the key strategies for business expansion as investments in biosimilars manufacturing helps in the fast market reach of the biopharmaceuticals. Moreover, biosimilars have supported the biopharmaceutical CMO industry with respect to cost-saving advantages.
Source Insights
The mammalian source segment led the market in 2021 and accounted for the highest share of over 59%. An intensive investigation that is being carried out on the usage of various source and species for biopharmaceutical development is expected to drive the market growth. The main objective of these investigations is to enhance the productivity and efficiency of biopharmaceutical manufacturing. A major percentage of biopharmaceutical products that are in pipeline are mammalian expressed, hence the segment will retain the leading position over the forecast period as well.
The non-mammalian source segment is estimated to register the fastest CAGR from 2021 to 2028. Non-mammalian cell line -E. Coli is recognized as the widely adopted non-mammalian cell culture for biopharmaceutical production owing to its easy access and cost-effective cultivation. The development of a transgenic non-mammalian expression system holds great promise for the significant growth of this segment during the forecast period. Abbott Bioresearch, Avecia Biotechnology, BioReliance, Biovitrum AB, Dow Pharmaceutical, and Celltrion are few companies working as CMOs using microbial cultures.
Regional Insights
With a high number of biomanufacturing facilities in the U.S., North America dominated the global market and held the largest revenue share of over 34.4% in 2021. Furthermore, revenue from biopharmaceutical-based R&D activities held a major percentage out of the total R&D carried out in various sectors in the U.S.
However, Asia Pacific is expected to emerge as the fastest-growing regional market from 2022 to 2030. Low manufacturing and operating costs in countries like China and India are some of the key factors driving the regional market. Faster growth in the Korean market is also expected to boost revenue generation from the APAC region.
Some of the prominent players in the Biologics Contract Manufacturing Market include:
- Boehringer Ingelheim GmbH
- Lonza
- Inno Biologics Sdn Bhd
- Rentschler Biotechnologie GmbH
- JRS Pharma
- AGC Biologics
- ProBioGen
- Fujifilm Diosynth Biotechnologies U.S.A., Inc.
- Toyobo Co., Ltd.
- Samsung BioLogics
- Thermo Fisher Scientific, Inc.
- Binex Co., Ltd.
- WuXi Biologics
- AbbVie, Inc.
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
- By Source
- Mammalian
- Non-mammalian
- By Service
- Process Development
- Downstream
- Upstream
- Fill & Finish Operations
- Analytical & QC Studies
- Packaging
- Process Development
- By Product
- Biologics
- Monoclonal Antibodies (MABs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi, & Molecular Therapy
- Others
- Biosimilars
- Biologics
By Geography
North America
- U.S.
- Canada
Europe
- Germany
- France
- United Kingdom
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of Middle East & Africa
Click Here to View Full Report Table of Contents
Buy this Research Report@ https://www.novaoneadvisor.com/report/checkout/6297
You can place an order or ask any questions, please feel free to contact at sales@novaoneadvisor.com | +1 9197 992 333